Obinutuzumab ,Gazyva ,CD20 ,GA101 ,CAS No.949142-50-1 ,Anti-CD20 monoclonal antibody (Type II) ,Humanized glycoengineered IgG1 antibody ,Oncology biologic / CLL biologic / Follicular lymphoma biologic
Obinutuzumab ,Gazyva ,CD20 ,GA101 ,CAS No.949142-50-1 ,Anti-CD20 monoclonal antibody (Type II) ,Humanized glycoengineered IgG1 antibody ,Oncology biologic / CLL biologic / Follicular lymphoma biologic
Trade Name
Gazyva
Target
CD20
Molecular Type
Monoclonal Antibody
Sales In 2025 (Millions Of USD)
784(First Three Quarters)
Product Description
Detailed Specifications & Features
Trade Name : Gazyva
Target : CD20
Molecular Type : Monoclonal Antibody
Sales in 2025 (Millions of USD) : 784(First three quarters)
All detailed product information shall be subject to the issued final COA.
Should you need further in-depth documentation for this item, kindly get in touch with us.
